Acetyl-L-carnitine monograph

Alternative Medicine Review

Volumn 15, Issue 1, 2010, Pages 76-83

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

LEVACECARNINE;

AGITATION; ALCOHOLISM; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN ISCHEMIA; CATARACT; CLINICAL TRIAL; DEPRESSION; DIABETIC NEUROPATHY; DRUG ACTIVITY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG RESEARCH; FRAGILE X SYNDROME; HEPATIC ENCEPHALOPATHY; HUMAN; MALE INFERTILITY; NAUSEA; PERIPHERAL NEUROPATHY; PEYRONIE DISEASE; REVIEW; SIDE EFFECT; VOMITING;

ACETYLCARNITINE; ALCOHOLISM; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COGNITION; DEPRESSION; DIABETIC NEUROPATHIES; EVIDENCE-BASED MEDICINE; HEPATIC ENCEPHALOPATHY; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; NOOTROPIC AGENTS; VITAMIN B COMPLEX;

EID: 77952496964     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Murray M, Pizzorno J. Encyclopedia of Natural Medidne. Rocklin, CA: Prima Publishing; 1998:230.
2. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991;41:1726-1732.
3. Furlong JH. Acetyl-L-carnitine: metabolism and applications in clinical practice. Altern Med Rev 1996;1:85-93.
4. Kwon OS, Chung YB. HPLC determination and pharmacokinetics of endogenous acetyl-L-carnitine (ALC) in human volunteers orally administered a single dose of ALC. Arch Pharm Res 2004;27:676-681.
5. Parnetti L, Gaiti A, Mecocci P, et al. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol 1992;42:89-93.
6. Marcus R, Coulston AM. Water-soluble vitamins: the vitamin B complex and ascorbic acid. In: Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics. 9th Ed. New York, NY: McGraw-Hill; 1996:1567-1568.
7. Purpura DP, Girado M, Smith TG, et al. Structure-activity determinants of pharmacological effects of amino acids and related compounds on central synapses. J Neurochem 1959;3:238-268.
8. Hayashi K. Action of carnitine on excitable tissues of vertebrates. In: Peeters H, ed. Protides of the Biological Fluids. Amsterdam, Netherlands: Elsevier; 1960:371-381.
9. Perez Polo JR, Werrbach-Perez K, Ramacci MT, et al. Role of nerve growth factors in neurological disease. In: Agnoli A, Cahn J, Lassen N, et al, eds. Senile Dementias. 2nd International Symposium. Paris, France: Libby; 1988:15-25.
10. Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-L-carnitine. Ann N Y Acad Sci 2005;1053:153-161.
11. Bagetta V, Barone I, Ghiglieri V, et al. Acetyl-L-carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 2008;55:223-229.
12. Hart AM, Wilson AD, Montovani C, et al. Acetyl-L-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004;18:1549-1560.
13. Famularo G, Moretti S, Alesse E, et al. Reduction of glutamate levels in HIV-infected subjects treated with acetylcarnitine. J NeuroAIDS 1999;2:65-73. (Pubitemid 30012143)
14. Rai G, Wright G, Scott L, et al. Doubleblind, placebo controlled study of acetyl-L-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 1990;11:638-647.
15. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol 1986;24:511-516. (Pubitemid 16014637)
16. Sano M, Bell K, Cote L, et al. Doubleblind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49:1137-1141.
17. Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology 2000;55:805-810.
18. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003;18:61-71. (Pubitemid 36343974)
19. Gecele M, Francesetti G, Meluzzi A. Acetyl-L-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dementia 1991;2:333-337.
20. Angelucci L, Ramacci MT. Hypothalamo-pituitary-adrenocortical functioning in aging: effects of acetyl-L-carnitine. In: DeSimone C, Martelli EA, eds. Stress, Immunity and Aging, A Role for Acetyl-L-Carnitine: Proceedings of the Workshop Held in Pomezia, Rome, Italy Organised by Sigma Tau, 13 September. Amsterdam, Netherlands: Elsevier; 1989.
21. Tempesta E, Casella L, Pirrongelli C, et al. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987;13:417-423.
22. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990;16:101-106. (Pubitemid 20191237)
23. Akiskal HS. Dysthymic disorder: psychopathology of proposed chronic depressive subtypes. Am J Psychiatry 1983;140:11-20.
24. Zanardi R, Smeraldi E. A double-blind, randomized, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006;16:281-287.
25. http://www.hmc.psu.edu/childrens/healthinfo/f/fragilex.htm [Accessed January 7, 2010]
26. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 1995;95:744-752.
27. Handen BL, Feldman H, Gosling A, et al. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 1991;30:241-245.
28. Torrioli MG, Vernacotola S, Mariotti P, et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 1999;87:366-368.
29. Torrioli MG, Venacotola S, Peruzzi L, et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 2008;146:803-812. (Pubitemid 351499783)
30. Fedele D, Giugliano D. Peripheral diabetic neuropathy. Current recommendations and future prospects for its prevention and management. Drugs 1997;54:414-421.
31. Ido Y, McHowat J, Chang KC,et al. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes 1994;43:1469-1477.
32. Onofrj M, Fulgente T, Melchionda D, et al. L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain. Int J Clin Pharmacol Res 1995;15:9-15.
33. Lowitt S, Malone JI, Salem AF, et al. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 1995;44:677-680.
34. De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study. Drugs R D 2002;3:223-231.
35. Sima AA, Calvani M, Mehra M, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005;28;89-94. (Pubitemid 40095788)
36. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf 1998;19:481-494. (Pubitemid 29015407)
37. Herzmann C, Johnson MA, Youle M. Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials 2005;6:344-350. (Pubitemid 43336969)
38. Osio M, Muscia F, Zampini L, et al. Acetyl-L-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst 2006;11:72-76. (Pubitemid 43344978)
39. Youle M, Osio M, ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007;8:241-250. (Pubitemid 46691695)
40. Flatters SJ, Xiao WH, Bennett GJ. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci Lett 2006;397:219-223.
41. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005;41:1746-1750. (Pubitemid 41132636)
42. Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005;91:135-138. (Pubitemid 40705085)
43. Di Marzio L, Moretti S, D'Alo S, et al. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol 1999;92:103-110. (Pubitemid 29315991)
44. Elanchezhian R, Ramesh E, Sakthivel M, et al. Acetyl-L-carnitine prevents selenite-induced cataractogenesis in an experimental animal model. Curr Eye Res 2007;32:961-971. (Pubitemid 350135719)
45. Geraldine P, Sneha BB, Elanchezhian R, et al. Prevention of selenite-induced cataractogenesis by acetyl-L-carnitine: an experimental study. Exp Eye Res 2006;83:1340-1349. (Pubitemid 44648094)
46. Elanchezhian R, Sakthivel M, Geraldine P, Thomas PA. The effect of acetyl-L-carnitine on lenticular calpain activity in prevention of selenite-induced cataractogenesis. Exp Eye Res 2009;88:938-944.
47. Swamy-Mruthinti S, Carter AL. Acetyl-L-carnitine decreases glycation of lens proteins: in vitro studies. Exp Eye Res 1999;69:109-115. (Pubitemid 29335457)
48. Calvani M, Arrigoni-Martelli E. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 1999;21:1-6. (Pubitemid 29386085)
49. Rosenthal RE, Williams R, Bogaert YE, et al. Prevention of postischemic canine neurological injury through potentiation of brain energy metabolism by acetyl-L-carnitine. Stroke 1992;23:1312-1317.
50. Aureli T, Miccheli A, Di Cocco ME, et al. Effect of acetyl-L-carnitine on recovery of brain phosphorus metabolites and lactic acid level during reperfusion after cerebral ischemia in the rat - study by 13P- and 1H-NMR spectroscopy. Brain Res 1994;643:92-99. (Pubitemid 24115081)
51. Rosadini G, Marenco S, Nobili F, et al. Acute effects of acetyl-L-carnitine on regional cerebral blood flow in patients with brain ischaemia. Int J Clin Pharmacol Res 1990;10:123-128. (Pubitemid 20377887)
52. Lenzi A, Sgro P, Salacone P, et al. A placebo-controlled, double-blind randomized trial of the use of combined L-carnitine and L-acetyl-carnitine treatment in men with asthenozoospermia. Fertil Steril 2004;81:1578-1584. (Pubitemid 38749002)
53. Balercia G, Regoli F, Armeni T, et al. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril 2005;84:662-671. (Pubitemid 41317725)
54. http://www.peyronies-disease-help.com [Accessed January 8, 2010]
55. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001;88:63-67. (Pubitemid 33755042)
56. Di Giacomo C, Latteri F, Fichera C, et al. Effect of acetyl-L-carnitine on lipid peroxidation and xanthine oxidase activity in rat skeletal muscle. Neurochem Res 1993:18:1157-1162. (Pubitemid 23306350)
57. Paradies G, Petrosillo G, Gadaleta MN, Ruggiero FM. The effect of aging and acetyl-L-carnitine on the pyruvate transport and oxidation in rat heart mitochondria. FEBS Lett 1999;454:207-209. (Pubitemid 29304601)
58. Ruggenenti P, Cattaneo D, Loriga G, et al. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension 2009;54:567-574.
59. McMackin CJ, Widlansky ME, Hamburg NM, et al. Effect of combined treatment with alpha-lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007;9:249-255.
60. Cha YS, Sachan DS. Acetylcarnitine-mediated inhibition of ethanol oxidation in hepatocytes. Alcohol 1995;12:289-294.
61. Sachan DS, Cha YS. Acetylcarnitine inhibits alcohol dehydrogenase. Biochem Biophys Res Commun 1994;203:1496-1501.
62. Tempesta E, Troncon R, Janiri L, et al. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. Int J Clin Pharmacol Res 1990;10:101-107. (Pubitemid 20377884)
63. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 2008;53:3018-3025.
64. Malaguamera M, Pistone G, Astuto M, et al. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 2006;51:2242-2247.
65. Janiri L, Martinotti G, Tonioni F, et al. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome. Clin Neuropharmacol 2009;32:35-40.
66. Memeo A, Loiero M. Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study. Clin Drug Investig 2008;28:495-500. (Pubitemid 351948052)
67. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004;218:103-108. (Pubitemid 38169402)